Cytokinetics (NASDAQ: CYTK) director receives 95-share equity grant

Rhea-AI Filing Summary

Cytokinetics director Wendell Wierenga received a stock grant of 95 shares of Common Stock as part of the company’s Director Equity in Lieu of Cash Retainer Program. The shares are fully vested, meaning they are not subject to additional service conditions.

Following this equity award, Wierenga directly holds a total of 32,637 shares of Cytokinetics Common Stock. This Form 4 reflects a routine compensation-related acquisition rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WIERENGA WENDELL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	95	$65.37	$6K

Holdings After Transaction: Common Stock — 32,637 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Stock grant size: 95 shares Grant price: $65.37 per share Post-transaction holdings: 32,637 shares

3 metrics

Stock grant size 95 shares Director equity grant on April 15, 2026

Grant price $65.37 per share Reported value for Common Stock grant

Post-transaction holdings 32,637 shares Total Common Stock held directly after grant

Key Terms

Director Equity in Lieu of Cash Retainer Program, fully vested, Grant, award, or other acquisition

3 terms

Director Equity in Lieu of Cash Retainer Program financial

"Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program."

fully vested financial

"Shares of common stock granted ... Shares are fully vested."

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIERENGA WENDELL

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		A(1)		95	A	$65.37	32,637	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested.

	/s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CYTK director Wendell Wierenga report?

Director Wendell Wierenga reported receiving a grant of 95 shares of Cytokinetics Common Stock. The award was issued under a Director Equity in Lieu of Cash Retainer Program and represents compensation, not an open-market trade, according to the Form 4 details.

At what price were the 95 CYTK shares granted to the director?

The 95 shares of Cytokinetics Common Stock were granted at a reported price of $65.37 per share. This value typically reflects the fair market value used for compensation purposes under the Director Equity in Lieu of Cash Retainer Program.

How many CYTK shares does Wendell Wierenga hold after this grant?

After the grant, Wendell Wierenga directly holds 32,637 shares of Cytokinetics Common Stock. This total includes the newly awarded 95 fully vested shares reported in the Form 4 insider transaction filing for the director.

Is the CYTK director’s 95-share grant subject to vesting conditions?

No, the 95-share grant to the Cytokinetics director is fully vested. The footnote explains that the Common Stock was granted under a Director Equity in Lieu of Cash Retainer Program and that the shares are fully vested when issued as compensation.

Was this CYTK insider transaction a market buy or sell?

This transaction was neither a market buy nor a sell; it was a compensation-related grant. The Form 4 uses transaction code A, indicating a grant or award acquisition, and the shares were issued under a Director Equity in Lieu of Cash Retainer Program.